Opthea Limited Sponsored ADR (OPT) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Opthea Limited announces strategic executive team changes, including the appointment of Daniel Geffken as interim CFO and Mike Campbell as CCO, in preparation for the Phase 3 topline data readouts of their retina treatment in 2025. The company has also strengthened its leadership with new hires in Biometrics, Clinical Operations, and Market Access, aiming to bolster their expertise in retina diseases and enhance their commercial capabilities. These changes come as Opthea progresses towards the potential launch of sozinibercept for wet age-related macular degeneration.
For further insights into OPT stock, check out TipRanks’ Stock Analysis page.
